LTI-03 was shown to reduce inflammation and scarring in lung tissue collected from IPF patients and analyzed in a lab, ...

GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing ...

For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.

As she plans her return to university teaching, columnist Ann Reynoso realizes how PF has given her a range of new skills for ...

Columnist Sam Kirton thought he'd meticulously prepared for his vacation, with all his medications in store. Then an illness took him down.

Using a specialized lab technique, scientists identified early cellular changes that may help drive lung scarring in pulmonary fibrosis.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...